Connect with us

Business

CSL (ASX:CSL) share price on watch after terminating COVID-19 vaccine trial

Published

on

The CSL Limited (ASX: CSL) share price will be one to watch on Friday after the release of an update on its COVID-19 vaccine candidate.

What did CSL announce?

This morning CSL and the University of Queensland (UQ) announced results from the Phase 1 trial of the UQ-CSL v451 COVID-19 vaccine.

According to the release, the vaccine has shown that it elicits a robust response towards the virus and has a strong safety profile.

And while there were no serious adverse events or safety concerns reported, following agreement with the Australian Government, CSL will not progress the vaccine candidate to Phase 2/3 clinical trials.

Why is it not going any further?

The release explains that the Phase 1 data showed the generation of antibodies…



Click here to view the original article.

Continue Reading
Advertisement
Advertisement

Trending